PDS Biotechnology Corp (PDSB)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.220.00%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · PDSB
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Expenses & Income | ||||||||||||
| R&D Expenses | 15.7 | 19.0 | 22.6 | 27.8 | 29.4 | 11.3 | 7.9 | 6.1 | 0.8 | 34.3 | 24.8 | 17.8 |
| Operating Income | (27.8) | (31.5) | (36.3) | (43.0) | (41.7) | (21.4) | (14.9) | (21.0) | (3.6) | (52.0) | (39.5) | (26.5) |
| Earnings from Continuing Operations | ||||||||||||
| Interest Expense | — | 5.3 | 4.7 | 4.2 | 1.3 | 0.0 | 0.0 | 0.0 | 0.0 | 2.2 | 1.2 | 0.8 |
| Interest & Investment Income | 0.8 | 1.2 | 2.5 | 2.9 | 0.9 | 0.0 | 0.1 | 0.4 | 0.9 | 0.7 | 0.2 | 0.0 |
| Net Interest Expenses | — | — | — | 1.3 | 0.4 | (0.0) | (0.1) | (0.3) | (0.9) | 1.5 | 1.0 | 0.8 |
| Other Non-Operating Income / Expenses | — | — | — | — | — | — | — | (0.2) | — | — | — | — |
| EBT, Incl. Unusual Items | (33.7) | (35.7) | (38.5) | (44.3) | (42.1) | (21.4) | (14.8) | (7.4) | (3.8) | (53.4) | (40.7) | (29.2) |
| Income Tax Expense | — | (1.2) | (0.9) | (1.4) | (1.2) | (4.5) | 0.0 | (0.4) | 0.0 | (2.6) | (1.8) | (1.1) |
| Net Income | ||||||||||||
| Net Income | (33.7) | (34.5) | (37.6) | (42.9) | (40.9) | (16.9) | (14.8) | (7.0) | (3.8) | (50.9) | (38.8) | (28.1) |
| Per Share | ||||||||||||
| Basic EPS | (0.60) | (0.74) | (1.03) | (1.39) | (1.43) | (0.66) | (0.89) | — | — | — | — | — |
| Diluted EPS | (0.60) | (0.74) | (1.03) | (1.39) | (1.43) | (0.66) | (0.89) | — | — | — | — | — |
| Basic Weighted Avg Shares | 55.7 | 46.4 | 36.5 | 31.0 | 28.6 | 25.6 | 16.7 | — | — | — | — | — |
| Diluted Weighted Avg Shares | 55.7 | 46.4 | 36.5 | 31.0 | 28.6 | 25.6 | 16.7 | — | — | — | — | — |
| Supplemental | ||||||||||||
| EBITDA | — | — | — | — | — | — | (14.9) | (21.0) | — | — | — | — |
| EBIT | (27.8) | (31.5) | (36.3) | (43.0) | (41.7) | (21.4) | (14.9) | (21.0) | (3.6) | (52.0) | (39.5) | (26.5) |
| Effective Tax Rate | — | — | — | 3.2% | 2.9% | 21.1% | 0.0% | 5.2% | 0.0% | 4.8% | 4.5% | 3.8% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.